

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 February 2006 (09.02.2006)

PCT

(10) International Publication Number
WO 2006/015031 A2

(51) International Patent Classification:

A61F 2/00 (2006.01)

(21) International Application Number:

PCT/US2005/026614

(22) International Filing Date: 27 July 2005 (27.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/591,648 28 July 2004 (28.07.2004) US

60/700,857 20 July 2005 (20.07.2005) US

(71) Applicant (for all designated States except US):
ETHICON, INC. [US/US]; U.S. Route #22, Somerville,
New Jersey 08876-0151 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SMITH, Daniel J.**
[US/US]; 12 Garfield Court, Dayton, New Jersey 08810
(US). **TRACEY, Michael** [US/US]; 403 Kacey Court,
Branchburg, New Jersey 08876 (US). **LANDGREBE,**
Susanne [DE/DE]; Zuckerhut 3, 23867 Sulfeld (DE).

(74) Agents: **JOHNSON, Philip S.** et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, New Jer-
sey 08901-9988 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

[Continued on next page]

(54) Title: MINIMALLY INVASIVE MEDICAL IMPLANT AND INSERTION DEVICE AND METHOD FOR USING THE SAME



(57) Abstract: A medical implant and method for implantation of the same. One embodiment is an implant for use in the treatment of stress urinary incontinence that includes an implantable, elongated tape having a multiplicity of openings formed through the thickness thereof, the tape having a first end region and a second end region longitudinally opposite the first end region, and first and second bio-compatible fixation elements attached to the first and second end regions of the tape respectively. Each bio-compatible fixation element has a tissue adherence property greater than that of the tape.

WO 2006/015031 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

MINIMALLY INVASIVE MEDICAL IMPLANT AND INSERTION DEVICE AND METHOD FOR USING THE SAME

BACKGROUND OF THE INVENTION

Cross Reference to Related Applications

The present application claims priority to U.S. Provisional Patent Application Serial Nos. 60/591,648, filed on July 28, 2004, and _____, filed on July 20, 2005.

5 Field of the Invention

This invention relates generally to minimally invasive medical implants and procedures for their use and insertion device for implanting the same, having particular application for treating urinary incontinence.

Description of the Prior Art

10 Stress urinary incontinence (SUI) is a female medical condition commonly associated with weakening of the pelvic muscles and/or connective tissues that support the urethra in its proper position. As a result of this condition, involuntary urine leakage occurs from simple physical activity, such as running or jumping, and even coughing or sneezing, as the urethra is not properly supported and does not remain fully
15 closed during such activity.

A widely accepted medical procedure to correct SUI is the insertion of a tension-free or trans-vaginal tape that is surgically implanted in the pelvic tissue and that extends under and provides support for the urethra when pressure is exerted thereon.

20 U.S. Patent No. 5,899, 909, the disclosure of which is incorporated herein by reference, describes in detail a typical procedure for treating SUI using a trans-vaginal tape. The tape is implanted by passing an elongated curved needle that is attached to one end of the tape through an incision in the vaginal wall, to one lateral side of the

urethra, through the pelvic tissue behind the pubic bone, and exiting out through an incision made in the abdominal wall. The procedure is repeated for the other end of the mesh tape, this time on the other lateral side of the urethra, with the needle exiting through a second incision made in the abdominal wall of the patient. After the mesh tape is adjusted for proper support of the urethra, its free ends extending outside of the abdominal wall are trimmed. Over time, fibroblasts grow into the mesh tape to anchor the tape in the surrounding tissue. Thus, the tape is left as an implant in the body to form an artificial ligament supporting the urethra in order to restore urinary continence. In another known method for implanting a trans-vaginal tape, the tape is inserted in a somewhat similar manner, but is brought out through the obturator hole and exits the body through a small incision in the upper leg.

The use of trans-vaginal tape for treating SUI has a number of advantages. It does not need to be attached through bone anchors, sutures or any other element to secure the tape in place, and there is minimal scarring. The procedure takes about 30 to 50 minutes, and may be performed on an outpatient basis under local, regional or general anesthesia. One of the few disadvantages of known procedures for implanting sub-urethral tapes is that the use of needles to pass the tape through the body poses a risk for vessel, bladder and bowel perforation. Also they require two separate, minimal incisions made through the abdominal wall (for a retropubic approach) or the upper leg (for an obturator approach) through which exit the curved needles and attached tape is passed. This, of course, increases the risk of post-operative pain and/or infection to at least a small degree.

Accordingly, what is needed is an improved sub-urethral tape, and device and method for implanting the same.

SUMMARY OF THE INVENTION

The present invention provides an implant for use in the treatment of stress urinary incontinence in a patient that includes an implantable, elongated tape having a multiplicity of openings formed through the thickness thereof, the tape having a first end region and a second end region longitudinally opposite the first end region, and first and second bio-compatible fixation elements attached to the first and second end regions of the tape

respectively, with each bio-compatible fixation element having a tissue adherence property greater than that of the tape.

Also provided is an implant for use in the treatment of stress urinary incontinence in a patient including an implantable, elongated tape having a multiplicity of openings
5 formed through the thickness thereof, the tape having a first end region and a second end region longitudinally opposite the first end region, and first and second bio-compatible fixation elements attached to the first and second end regions of the tape respectively, with each bio-compatible fixation element having a stiffness greater than that of the tape.

A method of implanting an implant in a patient for the treatment of stress urinary
10 incontinence is also provided, wherein the method includes the steps of providing an implant including an implantable, elongated tape portion having a multiplicity of openings formed through the thickness thereof, and having a first end region and a second end region longitudinally opposite the first end, and first and second bio-compatible fixation elements attached to the first and second end regions of the tape respectively. Each bio-compatible
15 fixation element has a tissue adherence property greater than that of the tape. The method further includes the steps of making an incision in the vaginal wall of the patient, inserting the first fixation element and attached tape through the incision and into the pelvic or any obturator tissue of the patient on one lateral side of the urethra and without exiting the body, inserting the second fixation element and attached tape through the incision and into
20 the pelvic or any obturator tissue of the patient and on an opposite lateral side of the urethra without exiting the body such that the tape forms a loop partially around the urethra to provide support for the urethra, and leaving the implant implanted in the body of the patient.

Finally, a method is also provided for implanting an implant in a patient for the
25 treatment of stress urinary incontinence which includes the steps of providing an implant including an implantable, elongated tape portion having a multiplicity of openings formed through the thickness thereof, and having a first end region and a second end region longitudinally opposite the first end, and first and second bio-compatible fixation elements attached to the first and second end regions of the tape respectively. Each bio-compatible
30 fixation element has a stiffness and/or tissue adherence property greater than that of the tape. The method further includes the steps of making an incision in the vaginal wall of the patient, inserting the first fixation element and attached tape through the incision and into connective tissue attached to the pubic bone to a first side of the patient's urethra, inserting

the second fixation element and attached tape through the incision and into connective tissue attached to the pubic bone on the opposite side of the patient's urethra such that the tape forms a loop partially around the urethra to provide support for the urethra, and leaving the implant implanted in the body of the patient.

5 The present invention also provides an implant for medical procedures having a mesh structure having a multiplicity of openings formed through the thickness thereof, with the mesh structure having at least a first connection region and a second connection region, and first and second bio-compatible fixation elements attached to the first and second connection regions respectively. The bio-compatible fixation elements each have a tissue
10 adherence property greater than that of the mesh.

Yet another implant for medical procedures is provided including a mesh structure having a multiplicity of openings formed through the thickness thereof, with the mesh structure having at least a first connection region and a second connection region, and first and second bio-compatible fixation elements attached to the first and second connection
15 regions respectively. The bio-compatible fixation elements have a substantially planar and rectangular configuration and have a stiffness greater than that of the mesh structure.

These and other objects, features and advantages of the present invention will be apparent from the following detailed description of illustrative embodiments thereof, which is to be read in connection with the accompanying drawings.

20 **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is an isometric view of one example, of a medical implant in accordance with the present invention which is particularly suited for treatment of stress urinary incontinence.

Figure 2 is a bottom isometric view of the implant shown in Figure 1.

25 Figure 3 is an enlarged isometric view of a portion of the implant formed in accordance with the present invention and shown in Figure 1.

Figure 4 is a partially exploded isometric view of the implant shown in Figure 1 and shown with one example of a protective sheath.

Figure 4A is a partially exploded isometric view of the implant shown in Figure 4 with another form of a protective sheath shown in an open state to receive the tape.

Figure 4B is an isometric view of the implant and protective sheath shown in Figure 4, the protective sheath being shown folded to at least partially envelop the tape.

5 Figure 4C is a partially exploded isometric view of the implant shown in Figure 4 with yet a further form of a protective sheath shown in an open state to receive the tape.

Figure 5 is a top plan view of a portion of an implant formed in accordance with another embodiment of the present invention.

10 Figure 6 is a cross-sectional view of the implant shown in Figure 5, taken along line 6-6 of Figure 5.

Figure 7 is a diagrammatic illustration of an implant of the present invention being surgically implanted in the body of a patient prior to sheath removal.

15 Figure 8 is one diagrammatic illustration of an implant of the present invention shown surgically implanted in the body of a patient after proper placement and sheath removal.

20 Figure 9 is a partial isometric and exploded view of one form of an insertion tool, shown overlying one end of an implant, both of which are formed in accordance with the present invention, for surgically implanting the implant in the body of a patient.

Figure 10 illustrates one end of another embodiment of an implant according to the present invention.

Figure 10a illustrates the shape of the implant of Fig. 10 when implanted and under tension.

25 Figure 11 illustrates another embodiment of an implant according to the present invention.

Figure 12 is a perspective view illustrating another embodiment of an insertion device according to the present invention.

Figure 12a illustrates the device of Fig. 12 with the implant holding element in a second position.

5 Figure 13 is a side view of the insertion device of Fig. 12.

Figure 14 is an enlarged view of the distal end region of the insertion device of Fig. 12 holding an implant.

Figures 15a-c illustrates various insertion steps using an implant and insertion device according to the present invention.

10 Figure 16 illustrates an alternative placement of an implant according to the present invention.

DETAILED DESCRIPTION

Although the present invention is described in detail in relation to its use as a sub-urethral tape for treating stress urinary incontinence, it is to be understood that the invention is not so limited, as there are numerous other applications suitable for such an
15 implant. For example, implants incorporating novel features described herein could be used for repairing pelvic floor defects such as, but not limited to, cystoceles and rectoceles, and for hernia repair or other prolapse conditions, or for supporting or otherwise restoring other types of tissue.

20 Turning initially to Figures 1-3 of the drawings, one embodiment of an implant 2 in the form of a sub-urethral tape particularly suited for the treatment of stress urinary incontinence (SUI) includes an implantable, elongated tape 4. The main tape portion 4 has a multiplicity of openings formed through the thickness thereof, and includes a first end 6 and a second end 8 longitudinally opposite the first end 6.

25 Preferably, the tape 4 is formed as a mesh or netting with openings formed through the thickness thereof of the order of about 1 millimeter to allow fibroblasts to grow into the tape for securing the tape in the surrounding tissue of the patient. A suitable material for the tape is PROLENE[®], which is a knitted or woven polypropylene

mesh having a thickness of approximately 0.7 millimeters, and which is manufactured by Ethicon, Inc., Somerville, New Jersey. This material is approved by the FDA in the United States for implantation into the human body.

5 The PROLENE[®] tape mentioned above is a non-absorbable mesh. However, it is envisioned to be within the scope of the invention to have the tape 4 formed of a knitted or woven material or netting that is bioabsorbable over time, or that can vary in pore size, fiber thickness, construction, size and/or properties.

The elongated tape 4 may be coated on one or more sides with a fibroblast stimulating substance, for example, an enamel matrix derivative.

10 In a further embodiment shown in Figures 5 and 6, a plurality of spaced apart synthetic filament tangles 10 may be attached to the top side 12 and/or the opposite bottom side 14 of the tape 4 so as to extend outwardly from the surfaces of the top and bottom sides for stimulating scar tissue growth and attachment to the tape 4.

15 The visible mesh tape 4 will be suitably dimensioned in accordance with its application(s) as described. For example, one embodiment described in detail below that is particularly suitable for treatment of stress urinary incontinence in women has a width of approximately 10-12 millimeters, and has a length L_1 between about 15 millimeters and about 150 millimeters, preferably 40 millimeters. The total length of the implant L_2 including the fixation elements 16 can be from about 35 millimeters up to about 250 millimeters, and preferably about 80 mm millimeters. As will be explained in greater detail below, the length of the implant 2 may vary since the fixation elements 16 may be trimmed or cut transversely depending upon the insertion method and the needs of the physician during surgical implantation of the tape. Further, the length may vary according to the desired use and/or placement of the implant

25 Returning again to Figs. 1-3, the implant may further include a bio-compatible and preferably bio-absorbable polymer fixation element 16 attached to each of the first and second end regions 6, 8 of the visible main tape portion 4. In one embodiment, each bio-absorbable polymer fixation element 16 has tissue adherence properties for securing in vivo_ the implant to surrounding tissue of the patient in whom the implant is
30 implanted without requiring any other means for physical attachment such as anchoring

mechanisms or the like. By "tissue adherence property" what is meant is the ability of the implant to have relative immediate and positionable fixation (even if by temporary means) into sturdy tissue without the need for immediate tissue ingrowth. In yet another embodiment, the fixation elements simply have a stiffness greater than that of the main tape portion, which enables the fixation elements to be firmly held on to the insertion device, and when implanted within suitably sturdy tissue such as connective tissue, to be firmly held within the tissue. Other means for stiffening may also be used.

According to a preferred embodiment, the bio-absorbable fixation elements are created by assembling material or components of a product sold under the name ETHISORB[®] Dura Patch, sold by Codman, a Johnson & Johnson company, which is mainly a VICRYL[®] polyglactin synthetic surgical composite material which is used for tissue reinforcement in surgery. VICRYL[®] is a material manufactured by Ethicon, Inc. of Somerville, N.J. ETHISORB[®] Dura Patch includes a fleece made from VICRYL[®] (polyglactin 910) and PDS (poly-p-dioxanone) undyed yarn which is sandwiched on one side with a piece of dyed poly-p-dioxanone film. The film and fleece are bonded together in a thermal process, which leaves the film intact as a sheet. The film is dyed violet with D&C Violet No. 2 (color index No. 60725). According to one embodiment, the ends of the PROLENE[®] tape can be sandwiched between two pieces of ETHISORB[®] Dura patch, with the components being thermally bonded together.

According to a preferred embodiment, however, the VICRYL[®] and PDS components of ETHISORB[®] Dura patch are used to make the fleece portion, as well as the same dyed poly-p-dioxanone film. The separate components, the fleece pad and the dyed poly-p-dioxanone film sheet, are placed on one side of the PROLENE[®] tape and a second fleece pad and dyed poly-p-dioxanone film sheet are placed on other side. The 5-piece assembly is then placed into a thermal process to bond the components together. The thermal process is controlled to maintain the temperature such that it only will melt the PDS yarn and dyed poly-p-dioxanone film. Use of the separate components provides a non-pressed fleece that facilitates subsequent bonding of the two film sheets through the mesh, since the two fluffy fleece layers integrate into the weave of the PROLENE[®] mesh during pressing.

After the thermal pressing process, the dyed poly-p-dioxanone film sheets no longer exist, as they are melted forming a plethora of bond points between the mesh and fleece layers.

The fleece component described above is made from absorbable materials, but could conceivably be made from non-absorbable material or a combination thereof. The process of making the fleece starts similar to other textiles where relatively straight yarn is taken in a preferred ratio, with the ratio of VICRYL[®] to PDS in the preferred embodiment being approximately 8:1. The single yarn strands are spun together using common textile techniques, and the new strand is woven into a sock like structure that is approximately 1-2 inches in diameter and of a continuous length. The sock or tube like structure is woven so that the lead thread can be pulled to unravel the tube, which kinks the otherwise relatively straight 8:1 strand.

10 The sock or tube is fed into a loom, and a loose scarf-like material sheet is woven approximately 8 inches wide. Because the kinked 8:1 strand was used, the resulting scarf structure is fluffy. The scarf is then cut into lengths of approximately 12-18 inches. The cut length is then placed on a non heated plate, and a heated plate then dropped over the non-heated plate trapping the scarf between a defined gap. As
15 the temperature of the scarf increases to a predetermined temperature that is below the PDS yarns melting point, small melting points are generated that hold the shape of the new fluffy fleece structure. As the individual PDS yarn strands shrink and melt slightly they pull the VICRYL[®] yarn strands with it. Further, as the original scarf shrinks, it gets both thicker and smaller as the open weave of the scarf closes up. The resulting
20 new material is an exemplary "fleece like material" as referenced above.

Although one preferred embodiment is described above, it is recognized that improvements can be made that are intended to be within the scope of the present invention. For instance, one may alter the compositional ratio of absorbable polymers making up the material. That is, use more of the poly(L(-)-lactide-co-glycolide)
25 component and less of the poly(p-dioxanone) component, or vice versa. It is also recognized that in the case of the lactide/glycolide copolymer, one might alter the relative amounts of the co-monomers. Thus one might slightly increase the lactide level in the copolymer to reduce crystallinity and increase the rate at which the component is absorbed. It is also recognized that the geometrical nature of the fibrous components of the fleece can
30 be altered to provide enhanced gripping of the tissue surfaces. One may provide a more non-circular cross-section of the fibrous components, such as a cross-section that is flatter. A star-shaped cross-section might also be utilized to enhance gripping.

Further, other absorbable polymers might be utilized to advantage in practicing the present invention. Of particular utility are the absorbable or bioabsorbable polymers prepared from lactone monomers selected from the group consisting of p-dioxanone, glycolide, L(-)-lactide, D(+)-lactide, meso-lactide, ϵ -caprolactone and trimethylene carbonate or combinations thereof. In those surgical cases in which tissue repair is compromised, such as in diabetic or elderly patients, the absorption profile of the fixation elements might be adjusted accordingly. Thus, one might make use of a high-lactide (co)polymer, such as 95/5 poly(L(-)-lactide-co-glycolide) to advantage.

Besides the absorbable polymers prepared from lactone monomers described above, one might utilize oxidized regenerated cellulose, also known as ORC. This material, especially in a non-neutralized state, is known to adhere to bodily tissue. The extent of oxidation and acidity could be adjusted to enhance the adherence and also provide anti-bacterial activity.

In a further aspect of the invention, the absorbable polymers may be combined with antimicrobial agents to provide an added benefit. It is recognized that other active ingredients might be added to provide enhanced characteristics, such as pain reduction agents, etc. The agents may be added to the polymer prior to formation of the final material, added to the final material once fabricated, or added to the fixation elements once fabricated.

It would not be unreasonable to assume that there are certain surgical situations in which a non-absorbable permanent fixation elements would be preferred. In this case the fixation elements could be fabricated from a variety of materials, including but not limited to non-absorbable polymers, metals, or ceramics. Non-absorbable polymers include the polyolefins, such as polyethylene or polypropylene; polyurethanes; polyesters, such as polyethylene terephthalate or polybutylene terephthalate; and polyamides, also known as nylons, such as nylon-6, nylon-66, or nylon-12.

As shown in the embodiment of Figure 3 and as described above, each fixation element 16 may include a first top portion 18 and a second bottom portion 20. The first portion 18 is attached to the top side of the tape and the second portion 20 is attached to the bottom side of the tape. The tape may extend along only a portion of the length of the fixation element, or in alternate embodiments may extend fully along the length or

simply secured to the extreme ends of the tape. The fixation element portions 18, 20 may alternatively be attached to the tape 4 by other well-known methods, such as by using bio-compatible adhesives or the like.

5 The polymer fixation elements 16 of the embodiment of Figs. 1-3 include a central body portion 22 and a plurality of longitudinally spaced apart finger portions 24 extending outward laterally in opposite directions from the central body portion 22. Preferably, each finger portion 24 is generally triangular in shape, with the polymer fixation element 16 taking on a generally arrow configuration, with a broad base 26 at one end and a triangular or arrowhead-shaped tip portion 28 at the other end. The
10 plurality of triangular-shaped finger portions 24 extend laterally outwardly between the base 26 and triangular tip portion 28.

The triangular-shaped finger portions 24 may be spaced apart longitudinally from adjacent finger portions by about 3-5 millimeters, and the fingers on either side of the center portion may be shifted to further enhance adjustability. The width of each
15 polymer fixation element 16 measured between the most lateral extent of transversely disposed finger portions 24 is preferably about 11 millimeters, which is the preferred width of the tape 4 and the implant 2 overall. In an alternate embodiment, the fingers may be very closely spaced, on the order of 0.02 to 1.0 millimeters, and may have any configuration other than triangular, so as not to resemble visible fingers. The implant
20 may further include interruptions in the pitch between the "fingers." For example, in one preferred embodiment, the "fingers" are spaced apart longitudinally by approximately 0.05mm, with every other one removed. Alternatively, an irregular cut surface that has no defined spacing longitudinally along it can be used on one or both sides.

25 The finger portions 24 can be sharp, but preferably are formed with a radius of about 0.1 and 2 millimeter at their most laterally outwardly extending part 30, and are formed with a radius of about 0.1 and 2 millimeter at their most inwardly extending part 30, i.e., the area in between adjacent laterally outwardly extending portions 30 thereof, and the triangular tip 28 of each fixation element 16 has a transverse width of
30 about 11 millimeters and a longitudinal length that can vary from 3- 10 millimeters.

Furthermore, the fixation elements 16 may be trimmed or cut across their transverse width if the physician needs to shorten the overall length of the implant 2.

With this particular shape, the polymer fixation elements 16 are envisioned to adhere to and/or engage the surrounding tissue, minimizing backward slippage or forward sliding after the implant 2 is surgically implanted in the patient. It is preferred that each fixation element 16 have a stiffness that is greater than the stiffness of the mesh tape portion 4 in order to provide some rigidity and maintain its overall shape. This prevents or minimizes slippage with respect to the surrounding tissue to which they adhere and maintains the overall integrity of the fixation elements during surgical implantation. Stiffness of the whole fixation area can be changed through choice of manufacturing process.

Although the embodiment of Figs. 1-3 incorporates the finger portions described above, the fixation areas may also simply have a rectangular configuration, as shown in Fig. 10, so long as the fixation areas are comprised of a material having a suitable stiffness and/or tissue adhesive properties to secure the tape in place, such as the material described above. In the embodiment of Fig. 10, a lower edge 17 of the fixation area 16 has a cross-sectional area (along line a-a) that is slightly larger than that of the mesh to which it attaches. This difference in cross-sectional area may also be increased during implantation since typically the tension on the mesh causes the mesh to assume a slightly reduced width as shown in Fig. 10a.

As shown in Fig. 9 in particular, each fixation element 16 may further include one or more holes 34, openings, slits or the like formed through the thickness thereof and longitudinally spaced apart from each other. These holes 34 may cooperate with one embodiment of an insertion tool 36 for properly positioning the free ends of the implant 2 in the pelvic or obturator tissue of the patient. Such an insertion tool 36 may include an elongated rod 38 which may be bendable to a desired curvature by the physician and which retains its configured shape during the surgical procedure. The rod 38 includes a proximate end 40 for grasping by the physician, and a distal end 42 opposite the proximate end 40 for insertion through an incision made in the top vaginal wall of a patient. The distal end portion 42 includes one or more prongs 44 extending radially outwardly from the rod 38 and spaced apart from one another. Each prong 44

has a diameter that is equal to or slightly less than the diameter of the holes 34 formed in the fixation elements 16, and adjacent prongs 44 are separated from one another a distance equal to the spacing between adjacent holes 34 formed in the fixation elements. Accordingly, the prongs 44 of the insertion tool 36 are receivable by the
5 holes 34 formed in the fixation elements 16 so that each free end of the implant 2 may be selectively secured to the distal end 42 of the insertion tool for proper placement within the pelvic tissue of the patient. Once properly positioned, the implant 2 may be separated from the insertion tool 36 by the physician manipulating the proximate end in order to maneuver the distal end 42 of the insertion tool slightly away from the implant
10 2 so that the prongs 44 are released from their respective holes 34 in the fixation elements. Various other methods of insertion will also be apparent to those skilled in the art, such as any variation of a forcep used to position the fixation areas, or other insertion tools having suitable means by which to grasp and/or position the fixation areas of an implant. Another preferred embodiment of an insertion device will be
15 described in detail below.

A second reason for having such holes 34 formed through the thickness of the fixation elements 16 is that they facilitate the in-growth of tissue through the fixation elements to further adhere them to the surrounding tissue.

As shown in Figure 4 of the drawings, according to one embodiment, the
20 implant 2, and in particular the tape 4 is covered on its top and bottom sides with a removable plastic sheath 46. Each sheath 46 may include a cut or perforation 48 extending at least partially across its width at its midpoint that overlies the midpoint of the implant 2 to facilitate its removal from the top and bottom sides 12, 14 of the tape 4. It may further include a line or other marking 50 running transversely across the middle
25 of the sheath 46, with such line or other marking 50 being positioned at the midpoint of the implant 2 so as to indicate to the physician where the midpoint of the tape resides during the surgical implantation procedure. Forceps may be used to remove the sheath 46 from the top and bottom sides 12, 14 of the tape 4 during the implantation
30 procedure. The sheaths 46 may prevent the tape 4 from catching on the surrounding tissue during insertion and positioning of the implant 2 within the patient's body. Each sheath 46 preferably extends slightly beyond the width of the tape 4 to ensure that the top and bottom sides 12, 14 and the lateral edges of the tape 4 will not catch on the

surrounding tissue during the surgical procedure. A sheath may also allow protection against contamination or damage.

Other forms of protective sheaths are illustrated by Figures 4A - 4C. More specifically, Figures 4A - 4C illustrate protective sheaths for the implant that are
5 formed as wrappers that may be folded over the implant to at least partially envelop the tape during implantation.

Turning initially to Figures 4A and 4B, the protective sheath 46' includes a back piece 60, preferably formed of two segments 61 positioned end-to-end. In relation to the tape, the two segments 61 meet in preferably the middle of the tape and extend
10 perpendicularly outwardly from the outer surface of the back piece to define together a tab 62. Each segment 61 of the back piece 60 forming the tab 62 may be grasped by the physician using forceps to remove the protective sheath 46' from the implant 2 after it has been properly positioned and implanted in the patient.

The protective sheath 46' further includes foldable lateral pieces 64 attached to
15 and extending from opposite sides of the back piece 60 at least partially along the longitudinal length of the back piece. As can be seen in Figure 4B, the implant 2 and sheath 46' are assembled such that the bottom side of the implant rests on the inner surface of the back piece 62, and the lateral pieces 64 of the sheath are folded over the top side of the implant. The lateral pieces 64 of the sheath 46' may be dimensioned to
20 meet each other at their free edges along the longitudinal centerline of the implant, or may be dimensioned so that one lateral piece extends partially overlapping the other lateral piece.

Preferably, as shown in Figures 4A and 4B, the protective sheath 46' may further include axial end pieces 66 attached to and extending from opposite axial sides
25 of the back piece 60. Each axial end piece 66 is preferably dimensioned to have a width and length that conform to the width and length of the central body portion 22 of each fixation element 16 so that they cover only one side of the central body portion 22, leaving the other side of the central body portion 22, and both sides of the finger portions 24, exposed. In this way, during implantation and with the protective sheath
30 46' affixed to the implant 2, the exposed portions of the fixation elements 16 will contact and be able to adhere to the surrounding tissue of the patient.

Figure 4C illustrates another form of a protective sheath 46" for use with the implant of the present invention. This sheath 46" is the same as that shown in Figures 4A and 4B, except that it is formed in two longitudinally disposed, individually foldable halves, i.e., the back piece 60 and opposite lateral pieces 64 are each formed by two separable segments 68 positioned longitudinally to each other in an end-to-end fashion. Each half portion segment 68 of the sheath 46" may be removed separately in the same manner as described previously, that is, by the physician grasping portions of the sheath back piece forming the tab 62 with forceps, so that one half segment 68 of the sheath 46" may be removed, if desired, during partial implantation of the implant, or both half segments 68 may be removed after both ends of the implant 2 have been properly positioned and implanted in the patient.

Additionally, the tape 4 may have its top side 12 formed with one marking, such as a first color, and its bottom side 14 formed with another marking, such as a second color that is different from the first marking or color. This will allow the physician to know whether the tape 4 is or has twisted during the surgical implantation procedure. In other words, one of the top and bottom sides 12, 14 of the implant 2 should be facing toward the urethra as it is looped partially thereabout, and the other of the top and bottom sides 12, 14, having a different color or other marking which is visible to the physician, should be facing away from the urethra during its surgical implantation in the patient. Of course, it is envisioned that the sheath 46, 46', 46", instead of the implant 2, may be similarly colored or include distinguishing markings.

In addition to the mentioned markings on the fixation ends, the mesh or sheath may be marked to describe the center of the mesh loop or a zone may be marked to help the physician symmetrically locate the mesh loop relatively to the urethra during implantation.

Figures 7 and 8 illustrate one procedure for surgically implanting an implant 2 of the present invention in a patient to treat stress urinary incontinence (SUI). First, a small incision 52 is made in the top vaginal wall 54. The physician attaches the distal end 42 of the insertion tool 36 to one fixation element 16 of the implant 2 by inserting the prongs 44 into their corresponding holes 34 formed through the fixation element.

The physician may bend the insertion tool to whatever curvature he feels is necessary to aid in the implantation procedure.

By manipulating the proximate end 40 of the insertion tool 36, the physician directs the distal end 42 of the tool with one end of the implant 2 attached thereto
5 through the surgical incision 52 and into the soft tissue on one lateral side of the urethra 56 and behind the pubic bone 58. The transverse marking(s) 50 on the sheath 46, 46', 46" will indicate to the physician the midpoint or mid-zone of the implant 2 so that the physician can judge the extent of tissue penetration and whether further insertion is required. Due to its inherent tendency to adhere to the surrounding tissue, the fixation
10 element 16 secures the free end of the implant 2 to the surrounding tissue it contacts. The physician now manipulates the insertion tool 36 such that it frees itself of the fixation element 16 and is removed, leaving the first half of the implant 2 implanted in the patient.

With the described insertion concept, and after insertion of the first fixation
15 element, the physician may recognize that the implant is too long by comparing the middle marking or mid-zone of the implant with the position of the urethra. If necessary, the second fixation element 16 of the described implant may be trimmed to compensate for the difference in length. Once trimmed to length, the physician then attaches the distal end 42 of the insertion tool to the fixation element 16 at the other end
20 of the implant 2, and directs the tool again through the vaginal wall incision 52 and so as to pass through the soft tissue on the other lateral side of the urethra 56 and behind the pubic bone 58. The physician then separates the insertion tool 36 from the fixation element 16 at this second end of the implant 2 and removes the tool, leaving the tape in place and partially looped around preferably the middle of the urethra 56. The second
25 fixation area 16 adheres to the surrounding tissue it contacts and holds the second half of the implant 2 in place. During this procedure, the physician may check the color or other marking on the top and bottom sides 12, 14 of the implant 2 or the sheaths 46, 46', 46" to ensure that the tape is not twisted. If necessary, the physician may trim one or both fixation elements 16 to adjust the length of the implant.

30 The physician now uses forceps to separate and remove the plastic sheaths 46, 46', 46" that cover the top and bottom sides 12, 14 of the tape 4. The exposed tape is

left implanted in the patient so that, over time, fibroblasts will proliferate and grow into the tape for securing the tape in the surrounding tissue. The fixation elements 16 fulfill their purpose for temporarily securing the implant. After absorption of the ETHISORB, the complete mesh length (including the parts in between the fixation elements) will
5 have in-growth into surrounding tissue, leaving the implanted tape to provide support for the urethra 56.

Referring once again to the embodiments of Figs. 10, 10a and 14, another embodiment of an inserter particularly suited for use with the implants of the present disclosure is shown further in Figs. 12-14. The inserter 100 preferably includes a first
10 inserter device 102 having a contour or the like (see Fig. 13) that is particularly suited to substantially follow the desired insertion path as will be described further below. In the illustrated embodiment, the inserter includes a distal end region 103 including a tissue penetrating distal tip 104. The tissue penetrating distal tip preferably includes a cutting edge as opposed to a blunt edge. The first inserter device 102 includes a substantially
15 planar portion 108, and a proximal end region 106 including a substantially curved portion 110. The substantially planar portion preferably has a length l_1 of approximately 1.2 inches, and a width of approximately 0.32 inches. Further, the curved portion 110 preferably has a length l_2 of approximately 1.5 inches over approximately 50 degrees. Preferably, the substantially planar portion is tangent to the curved portion 110, and a
20 substantially straight proximal portion 113 of the first inserter device is positioned approximately 40 degrees to the tangent of the curved portion 110.

In the illustrated embodiment, the inserter also includes a stiffening element 116 that is coupled to and preferably has a substantially complementary periphery to the substantially planar portion of the first inserter device. The stiffening element provides
25 additional stiffness to the inserter in the area to which the implant is secured as will be described in greater detail below. The stiffening element preferably is spaced slightly apart from the first inserter device, on the order of approximately 0.006 inches, by a plurality of small protrusions 130 or the like on either the inserter device or the stiffening element in order to enhance the efficiency and effectiveness of gas sterilization procedures by
30 allowing sterilization gases to more freely flow between the parts. This stiffening element is a thin hardened material having an outer cutting edge 105, and a width w_1 that is slightly greater than that of the first inserter device 102, preferably on the order of 0.015 inches wider.

In the illustrated embodiment, the stiffening element also includes a first pass through element 132 that preferably is a spring type element. The first pass through element has a front portion 115 and a rear portion 117 (see Figs. 13 and 14), both of which preferably extend upward substantially perpendicularly from the stiffening element. As
5 will be described further below, when an implant is secured to the inserter, the first pass through element extends at least partially up through an aperture in the implant, so that the front portion 115 prevents rearward movement of the implant relative to the inserter and the rear portion 117 prevents forward movement of the implant relative to the inserter. Further, when an implant is secured to the inserter, the spring type nature of the first pass
10 through element biases it to return to a position that is more flush with the inserter. Thus, when the capture element 118 is retracted (as described below), the implant is more easily released. Finally, the rear portion 117 preferably has a length such that it fits within the thickness or profile of the inserter after the implant is released so that it does not snag or otherwise catch on tissue as the inserter is removed from the body following placement of
15 the implant.

The inserter 100 further includes an implant holding element 118 that is movably coupled to the inserter device in an area towards the proximal end of the inserter device, such that it can be moved relative to the first inserter device as indicated by the arrow shown in Fig. 13. The purpose for this will become apparent from the further description
20 below. For example, in the illustrated embodiment, the implant holding element 118 is comprised of single and double wire sections, which are held in place at multiple points. In the present embodiment, these multiple points include capture element 122, pass through elements 132, 114, and finger pad 140. Preferably, the finger pad 140 includes a projection 190 that extends between the two wires 191a, 191b, and acts as a stop against the portion at
25 which the two wires come together 192 to limit retraction of the implant holding element.

The distal end 120 of the implant holding element is removably coupled to the first inserter device, preferably by being received by a capture element 122 at the distal end of the inserter. By manipulation of the implant holding device by a user, however, the distal end of the implant holding element can be subsequently released from the capture element.
30 In particular, movement of the implant holding device in the direction of the arrow shown in Fig. 13 will move the implant holding device to a second position shown in Fig. 12a wherein the implant holding element does not extend through the pass through element and is not received within the capture element. In this second position it also will not extend

through the implant, thereby releasing the implant from the inserter device as will be readily understood by the further description below.

In the illustrated embodiment, the capture element 122 projects upwardly from a top surface of the stiffening element, and has an aperture 124 therein dimensioned to receive the distal end of the implant holding element. The capture element 122 also serves a second function in that it provides a buffer for the implant as it is inserted. Although this is a preferred embodiment, those skilled in the art will readily recognize that various forms and configurations for this capture element are possible so long as it serves the purpose of removably receiving the distal end of the implant holding element.

The inserter also preferably includes one or more pass through element (i.e., 132, 114) projecting upwardly from its top surface, and including one or more openings (i.e., 134, 119) therethrough. The openings may be of any configuration or shape so long as they allow the implant holding element to pass therethrough as shown best in Fig. 14. This feature at least partially maintains the position of the implant holding element relative to the inserter. Although the illustrated pass through elements are formed integral with the inserter, any pass through element suitable for at least partially maintaining the position of the capture element relative to the inserter could be used, such as suture loops or the like.

As indicated, the presently described inserter is particularly suited for use in conjunction with an implant similar in construction to that described in connection with Fig. 10, but having fixation elements 140 of the configuration shown in Fig. 14, which includes either substantially flat side edges 195a, 195b, or rough cut side edges as described above. In a preferred embodiment, the outermost width w_2 of the implant relative to the outermost width w_1 of the inserter has a ratio of approximately 1.4:1. This ratio is preferred to achieve a balance between insertion forces and user control as the implant is inserted into the connective tissue as described below. Lower and higher ratios offer different results depending on surgical needs and/or the type of tissue being penetrated. For example, lower ratios such as between 0.7 and 1.4 can increasingly reduce the insertion force and decrease the frictional forces of the implant on the surrounding tissue. These lower ratios, however, may offer less user control. Higher ratios, such as between 1.4 and 2.8 can increasingly raise the insertion force if used in tough tissue, but may not increase the insertion force in soft tissue.

Preferably, each of the fixation elements 140 are secured to the distal end region of the inserter device via the implant holding element 118 as shown. In the illustrated embodiment, the implant holding element 118 extends along and substantially adjacent to

the top surface 119 of the first inserter device until it reaches the substantially planar region. At some point along the substantially planar region it begins to extend away from the first inserter device so as to leave a space therebetween as shown in Fig. 13. While spaced apart from the first inserter device, the implant holding device passes through the aperture 134 in the first pass through element 132, with its distal end 120 subsequently being received within the capture element 122. As shown in Fig. 14, to secure the implant to the inserter, the implant holding element extends upwardly through the implant before its distal end is received within the capture element 122. Preferably, the implant includes one or more apertures 135 extending therethrough to facilitate extension of the implant holding element through it, and to permit the pass through element 132 to extend upwardly through it as well.

According to one embodiment, the inserter 100 further includes a gripping element or finger pad 140 or the like positioned in the vicinity of the proximal end of the device. The gripping element is fixedly secured to the first inserter device 102 and has any configuration suitable to enhance gripping and manipulation of the device. In the illustrated embodiment, the gripping element is configured to receive a user's index finger. Additionally it has a tapered distal end to allow easy entry as the inserter 100 is pushed into the body. The finger pad 140 may also contains radio opaque material commonly used in medical devices to aid in determining if a lost or missing component has not been accidentally left in the patient. The inserter also may include one or two protective covers (not shown) over the cutting edge of the stiffening element to protect against damage or injury from the cutting edge prior to insertion.

The inserter provides several distinct advantages when inserting the implants described herein, as it allows the implant to be secured to the insertion device in a manner that minimizes the profile of the overall system. This is important in applications such as those described above because it is desirable to minimize tissue trauma other than that which is directly necessary to insert the implant. This is also important for visualization when placing the implant, as it is critical that the inserter minimize obstructing the surgeon's view during implantation. Another important aspect of the presently described inserter is that it provides a means by which to release the implant following proper placement without further manipulation of the implant. Further, the inserter 100 in combination with the described implant allows for forward and reverse adjustment of the implant before final release, and enables superior tactile feel by the surgeon before release. This is a significant advantage in that proper sling placement and tension can be achieved

using the inserter device, and once this proper placement is achieved the implant is released without further movement. This is contrary to presently existing sling implants, where the mesh is initially implanted, then subsequently adjusted by pulling on the ends or center of the sling. Finally, the inserter device is designed so that it is *not* situated between the
5 implant and the urethra (as compared to an insertion device that might “sandwich” the mesh between two opposing components) during placement of the implant, which has advantages with regard to proper positioning of the implant and visualization.

Another advantageous feature of the inserter of the present invention is that at least the cross-section of the curved portion 110 of the first inserter device has a substantially
10 “v” shaped configuration 151, as can best be seen in Fig. 15b. This “v” shaped configuration enables the width w_3 of the curved portion to be reduced relative to the outermost width w_1 of the inserter, while still maintaining sufficient strength. It has been found that the reduced width relieves pressure against the urethra during placement of the implant. A larger width can place pressure against the urthra and cause a false positive,
15 resulting in incorrect mesh placement after the inserters are removed. In a preferred embodiment the ratio of widths w_1 to w_3 is 2:1

Preferred methods for using the insertion device of Fig. 12-14 will now be described in detail with reference to Figs. 15a-c and 16. An implant 2 having fixation
elements 16 is preferably provided to a user with two inserters such as that described
20 above, each secured to one end of the implant as shown in Fig. 15b. The patient is prepped for the procedure by draining the bladder, anesthetizing using local, regional or general anesthesia, and subsequently being placed in the lithotomy position. Using either forceps or an Allis clamp, the vaginal wall is grasped at each side of the urethra. A sagittal incision about 1.5 cm long, starting approximately 1.0 cm from the external urethral meatus, is then
25 made using a scalpel or the like. The incision will cover the mid-urethral zone and will allow for subsequent passage of the implant. Then, with a small pair of blunt scissors, two small paraurethral dissections of approximately 1.0 cm are made.

The proximal end 106 of one of the inserters is then grasped using any standard needle driver or holder 150 or the like, clamping over the holding element 118. For the
30 “U” placement the distal end 108 of the inserter device is then oriented in approximately the 11 o’clock position towards the ipsilateral shoulder. With an index finger on the finger pad, the first 152 inserter and attached implant is inserted through the vaginal incision and first pre-dissected paraurethral dissection as shown in Fig. 15a, with the distal end of the insert device remaining in close contact with the inferior-posterior aspect of the pubic bone

so that the implant is inserted into the connective tissue of the urogenital diaphragm. Insertion should stop when the insertion device is firmly in the connective tissue (approximately 4 cm from the distal end of the fixation element). The needle driver/holder is then uncoupled from the first inserter and coupled with the second inserter 154 in the same way. The process is then repeated on the other side of the urethra 156, leaving the insertion devices/implants as shown in Fig. 15b. The tape 4 should be placed tension free under the mid-urethra. Adjustments can be made as needed by further insertion or retraction with the first 152 or second 154 inserters. The implant is then released from both the first 152 and second 154 insertion devices by pulling on the respective implant holding elements 158, 160 as shown in Fig. 15c, rather than the mesh as is the case with other known devices. The insertion devices are removed and the incision closed, thereby completing the procedure.

According to another preferred method, the implant can be placed in a more lateral position as shown in Fig. 16, known to those skilled in the art as the "hammock" position. The procedure is substantially the same as that described above, except that the first inserter 152 is oriented in approximately the 9 o'clock position or parallel to the floor at an angle of approximately 45 degrees from the midline, towards the ischiopubic ramus. The distal end of the insertion device is inserted in close contact with the bone, but towards the obturator internus muscle, within which it is firmly secured. Adjustment is done with the inserter 100, not by pulling on the mesh.

The implants described herein may be advantageously implanted in a patient without the use of needles that pass through the whole body and without the need to form incisions in the abdominal wall, large pre-dissected tracts, or upper leg of the patient, and further without the need for bone anchors of the like. Not only is the procedure less emotionally traumatic to the patient than conventional procedures employing elongated curved needles, or hooked device that are used to snag and drag the mesh through the body, but also less invasive, as no incisions to the abdominal wall or upper leg of the patient are required. Because the actual implant of the present invention is smaller than conventional implants, this can potentially result in less surgical complications, less mesh rejections, and/or less mesh infections, and a shortened surgical procedure.

With the "U" implant placement of the present invention, the surgical implantation procedure may be performed on an outpatient basis under local, regional,

or general anesthesia. Also, the procedure for implantation requires the use of a cystoscope, although the passage has less risk, as with all surgical procedures that pass near a structure there is always a risk of injury. The safety of the patient is further improved during the surgical implantation procedure, as there is less chance for complications due to the fact that there is no need to direct the "U" implant placement if done properly does not travel near the bladder or bowel or any large vessels as devices minimally invasive placement is intended to be at the lower edge of the pubic synthesis in the connective tissue near the pubic bone.

The "hammock" placement may similarly be performed on an outpatient basis under local, regional, or general anesthesia. The safety of the patient is even further improved over the "U" during the surgical implantation procedure, as there is no risk, if done correctly, to the bladder or bowel or any large vessels since the device path is not into the space of retzius. Additionally, the present invention offers yet further safety to currently known "hammock" type procedures that pass by or near the obturator bundle, which contains the nerve and artery. The implant of the present invention is preferably affixed into the internous muscle and it is not large enough to pass near the obturator bundle.

As indicated previously, although the present invention has been described in detail in relation to a sub-urethral tape, the invention is not so limited. The fixation elements described above can be incorporated to serve as fixation points for any type of mesh used in surgical procedures, such as pelvic floor repair or hernia repair, or plastic surgery, or restructuring of tissue. For example a mesh 70 such as shown in Fig. 11 (the shape is for illustrative purposes only, as any shaped mesh can be used) can incorporate one or more connection regions 72 to which fixation elements 16 can be secured. In the case of pelvic floor repair, for example, the mesh could be sized and shaped to treat a cystocele, with the mesh being secured in place using the fixation elements in a manner similar to that described above. For any and all plastic surgery used to change tissue position, for example, the device may look similar to the present invention and the insertion device shape, any width ratios of the inserter to implant, use of a covering, connection method and size may be altered to suit to the surgical application being attempted.

Although illustrative embodiments of the present invention have been described herein with reference to the accompanying drawings, it is to be understood that the invention is not limited to those precise embodiments and that various other changes and modifications may be effected herein by one skilled in the art without departing
5 from the scope or spirit of the invention, as is limited only by the appended claims.

What Is Claimed Is:

1. An implant for use in the treatment of stress urinary incontinence in a patient, comprising:
an implantable, elongated tape having a multiplicity of openings formed through
5 the thickness thereof, the tape having a first end region and a second end region
longitudinally opposite the first end region; and
first and second bio-compatible fixation elements attached to the first and second
end regions of the tape respectively, each bio-compatible fixation element having a tissue
adherence property greater than that of the tape.
10
2. The implant according to claim 1, wherein the implant has a length of
approximately 5 to 10 centimeters.
3. The implant according to claim 1, wherein the tape is comprised of a polypropylene
15 mesh or netting.
4. The implant according to claim 1, wherein the implant further comprises a sheath
substantially covering the tape.
- 20 5. The implant according to claim 1, wherein the fixation elements substantially
surround the first and second end regions of the tape respectively.
6. The implant according to claim 1, wherein each fixation element further comprises
a central body portion and a plurality of spaced apart finger portions extending outwardly
25 laterally from the central body portion.
7. The implant according to claim 1, wherein the tape includes a top side and a bottom
side, the top side have a first marking thereon and the bottom side having a second marking
thereon, the second marking being different from the first marking to thereby distinguish
30 the top side from the bottom side.

8. The implant according to claim 1, wherein the tape includes a plurality of spaced apart filament tangles attached thereto.
9. The implant according to claim 1, wherein each fixation element is made from a material fabricated from a composite of a first polymer and a second polymer, the first polymer being prepared from monomers selected from the group of lactide and glycolide, and the second polymer being a poly(p-dioxanone) polymer, rich in poly(p-dioxanone).
10. The implant according to claim 9, wherein the first polymer is 10/90 poly(L(-)-lactide-co-glycolide), and the second polymer is poly(p-dioxanone).
11. The implant according to claim 10, wherein the first polymer is 95/5 poly(L(-)-lactide-co-glycolide), and the second polymer is poly(p-dioxanone).
12. The implant according to claim 1, wherein the fixation elements are made from ETHISORB® Dura Patch.
13. The implant according to claim 1, wherein the fixation elements have a substantially rectangular, planar configuration.
13. The implant according to claim 1, wherein the fixation elements have an outermost width substantially equal to a width of the tape.
14. An implant for use in the treatment of stress urinary incontinence in a patient, comprising:
an implantable, elongated tape having a multiplicity of openings formed through the thickness thereof, the tape having a first end region and a second end region longitudinally opposite the first end region; and
first and second bio-compatible fixation elements attached to the first and second end regions of the tape respectively, each bio-compatible fixation element having a stiffness greater than that of the tape.

15. The implant according to claim 14, wherein the fixation elements have a substantially rectangular, planar configuration.
16. The implant according to claim 14, wherein the fixation elements have an
5 outermost width substantially equal to a width of the tape.
17. The implant according to claim 14, wherein, when implanted, the implant has a length approximately within the range of 5 to 10 centimeters.
- 10 18. The implant according to claim 14, the tape is comprised of a polypropylene mesh or netting.
19. The implant according to claim 14, wherein each fixation element is made from a material fabricated from a composite of a first polymer and a second polymer, the first
15 polymer being prepared from monomers selected from the group of lactide and glycolide, and the second polymer being a poly(p-dioxanone) polymer, rich in poly(p-dioxanone).
20. The implant according to claim 21, wherein the first polymer is 10/90 poly(L-)-lactide-co-glycolide), and the second polymer is poly(p-dioxanone).
- 20 21. The implant according to claim 20, wherein the first polymer is 95/5 poly(L-)-lactide-co-glycolide), and the second polymer is poly(p-dioxanone).
22. The implant according to claim 14, wherein the fixation elements are made from
25 ETHISORB® Dura patch. 24. The implant according to claim 15, wherein each fixation element further comprises a central body portion and a plurality of spaced apart finger portions extending outwardly laterally from the central body portion.
23. A method of implanting an implant in a patient for the treatment of stress urinary
30 incontinence, the method comprising the steps of:

providing an implant including an implantable, elongated tape portion having a multiplicity of openings formed through the thickness thereof, and having a first end region and a second end region longitudinally opposite the first end, and first and second bio-compatible fixation elements attached to the first and second end regions of the tape
5 respectively, each bio-compatible fixation element having a tissue adherence property greater than that of the tape;

making an incision in the vaginal wall of the patient;

inserting the first fixation element and attached tape through the incision and into the pelvic or any obturator tissue of the patient on one lateral side of the urethra and
10 without exiting the body;

inserting the second fixation element and attached tape through the incision and into the pelvic or any obturator tissue of the patient and on an opposite lateral side of the urethra without exiting the body such that the tape forms a loop partially around the urethra to provide support for the urethra; and

15 leaving the implant implanted in the body of the patient.

24. A method of implanting an implant in a patient for the treatment of stress urinary incontinence, the method comprising the steps of:

providing an implant including an implantable, elongated tape portion having a
20 multiplicity of openings formed through the thickness thereof, and having a first end region and a second end region longitudinally opposite the first end, and first and second bio-compatible fixation elements attached to the first and second end regions of the tape respectively, each bio-compatible fixation element having a stiffness and/or tissue adherence property greater than that of the tape;

25 making an incision in the vaginal wall of the patient;

inserting the first fixation element and attached tape through the incision and into connective tissue attached to the pubic bone to a first side of the patient's urethra;

inserting the second fixation element and attached tape through the incision and into connective tissue attached to the pubic bone on the opposite side of the patient's urethra such that the tape forms a loop partially around the urethra to provide support for the urethra; and

5 leaving the implant implanted in the body of the patient.

25. The method according to claim 24, wherein the first and second inserting steps further comprise inserting the first and second fixation elements respectively into connective tissue at the lower edge of the pubic synthesis.

10

26. An implant for medical procedures, comprising:

a mesh structure having a multiplicity of openings formed through the thickness thereof, the mesh structure having at least a first connection region and a second connection region; and

15 first and second bio-compatible fixation elements attached to the first and second connection regions respectively, the bio-compatible fixation elements each having a tissue adherence property greater than that of the mesh.

27. The implant according to claim 26, wherein each fixation element is made from a
20 material fabricated from a composite of a first polymer and a second polymer, the first polymer being prepared from monomers selected from the group of lactide and glycolide, and the second polymer being a poly(p-dioxanone) polymer, rich in poly(p-dioxanone).

28. The implant according to claim 25, wherein the first polymer is 10/90 poly(L-)-
25 lactide-co-glycolide), and the second polymer is poly(p-dioxanone).

29. The implant according to claim 28, wherein the first polymer is 95/5 poly(L-)-
lactide-co-glycolide), and the second polymer is poly(p-dioxanone).

30. The implant according to claim 26, wherein the fixation elements are made from ETHISORB® Dura patch.

31. An implant for medical procedures, comprising:

5 a mesh structure having a multiplicity of openings formed through the thickness thereof, the mesh structure having at least a first connection region and a second connection region; and

first and second bio-compatible fixation elements attached to the first and second connection regions respectively, the bio-compatible fixation elements having a
10 substantially planar and rectangular configuration and having a stiffness greater than that of the mesh structure.

32. The implant according to claim 31, wherein each fixation element is made from a material fabricated from a composite of a first polymer and a second polymer, the first
15 polymer being prepared from monomers selected from the group of lactide and glycolide, and the second polymer being a poly(p-dioxanone) polymer, rich in poly(p-dioxanone).

33. The implant according to claim 32, wherein the first polymer is 10/90 poly(L-)-lactide-co-glycolide), and the second polymer is poly(p-dioxanone).

20

34. The implant according to claim 33, wherein the first polymer is 95/5 poly(L-)-lactide-co-glycolide), and the second polymer is poly(p-dioxanone).

35. The implant according to claim 31 wherein the fixation elements are made from
25 ETHISORB® Dura patch.

36. The implant according to claim 31, wherein the fixation elements have an outermost width substantially equal to a width of the tape.

30

1/14

FIG. 1





FIG. 2



21/14

FIG. 3





FIG. 4



3/14

FIG. 4A






FIG. 4B



4/14

FIG. 4C



5/14

FIG. 5






FIG. 6




6/14

FIG. 7



7/14

FIG. 8



8/14

FIG. 9




FIG. 10




FIG. 10a






FIG 11




10/14

FIG. 12



11/14

FIG. 12a



13/14




FIG. 15a




FIG. 15b




FIG 15c

14/14




FIG. 16

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 February 2006 (09.02.2006)

PCT

(10) International Publication Number
WO 2006/015031 A3

(51) International Patent Classification:
A61F 2/00 (2006.01)

(21) International Application Number:
PCT/US2005/026614

(22) International Filing Date: 27 July 2005 (27.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/591,648 28 July 2004 (28.07.2004) US
60/700,857 20 July 2005 (20.07.2005) US

(71) Applicant (for all designated States except US):
ETHICON, INC. [US/US]; U.S. Route #22, Somerville,
New Jersey 08876-0151 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SMITH, Daniel J.
[US/US]; 12 Garfield Court, Dayton, New Jersey 08810
(US). TRACEY, Michael [US/US]; 403 Kacey Court,
Branchburg, New Jersey 08876 (US). LANDGREBE,
Susanne [DE/DE]; Zuckerhut 3, 23867 Sulfeld (DE).

(74) Agents: JOHNSON, Philip S. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, New Jer-
sey 08901-9988 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AI, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: MINIMALLY INVASIVE MEDICAL IMPLANT AND INSERTION DEVICE AND METHOD FOR USING THE SAME



(57) Abstract: A medical implant and method for implantation of the same. One embodiment is an implant for use in the treatment of stress urinary incontinence that includes an implantable, elongated tape having a multiplicity of openings formed through the thickness thereof, the tape having a first end region and a second end region longitudinally opposite the first end region, and first and second bio-compatible fixation elements attached to the first and second end regions of the tape respectively. Each bio-compatible fixation element has a tissue adherence property greater than that of the tape.



(88) Date of publication of the international search report:
18 May 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2005/026614

A. CLASSIFICATION OF SUBJECT MATTER

A61F2/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/086205 A (GYNE IDEAS LIMITED; BROWNING, JAMES) 23 October 2003 (2003-10-23) page 35, line 23 - page 37, line 9; figures 1-4 page 50, line 2 - page 52, line 18 page 16, line 27 - page 17, line 5 page 33, line 29 - line 32 page 34, line 23 - line 29 page 44, line 9 - line 14	1,3,6,7, 12,13, 26,30,37
A		2,9,27
X	US 2003/191480 A1 (ULMSTEN ULF ET AL) 9 October 2003 (2003-10-09) paragraph [0027]; figures 1,2 paragraph [0023] ----- -/--	1,3,5, 13,26



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 November 2005

Date of mailing of the international search report

06-02-2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Neumann, E

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2005/026614

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 2002/156488 A1 (GELLMAN BARRY N ET AL) 24 October 2002 (2002-10-24) paragraph [0176]; figures -----</p>	4,7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2005/026614

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03086205	A	23-10-2003	AU 2003229899 A1	27-10-2003
			CA 2481275 A1	23-10-2003
			EP 1492459 A2	05-01-2005
			GB 2402343 A	08-12-2004

US 2003191480	A1	09-10-2003	WO 02069781 A2	12-09-2002
			US 2002128670 A1	12-09-2002

US 2002156488	A1	24-10-2002	NONE	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2005/026614

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 23-25
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-13, 26-30, 37

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-13,26-30,37

An implant comprising an elongated tape and fixation elements attached to the end regions of the tape wherein the fixation elements have an adherence property greater than that of the tape
(problem: to avoid physical attachment means such as anchoring mechanisms for securing the implant to surrounding tissue)

2. claims: 14-22,31-36,38

An implant comprising an elongated tape and fixation elements attached to the end regions of the tape wherein the fixation elements have a stiffness greater than that of the tape
(problem: enabling the fixation elements to be firmly held on to the insertion device)
